Evidence map›Paper›PMID 42620868›Full record

ArticleFrontiers in immunology2026

Case Report: Immune-directed post-transplant maintenance with low-dose gemtuzumab ozogamicin and stepwise donor lymphocyte infusion in acute myeloid leukemia with t(1;3)(p36.3;q21).

Fumihiko Ouchi, Yuho Najima, Kyoko Haraguchi, Daichi Sadato, Chizuko Hirama, Kaoru Morita, Takashi Toya, Hiroaki Shimizu, Tomomi Toubai, Hironori Harada and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fumihiko OuchiHematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Yuho NajimaHematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Kyoko HaraguchiDivision of Transfusion and Cell Therapy, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Daichi SadatoClinical Research and Trials Center, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Chizuko HiramaClinical Research and Trials Center, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Kaoru MoritaHematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Takashi ToyaHematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Hiroaki ShimizuHematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Tomomi ToubaiHematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Hironori HaradaHematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Yuka HaradaClinical Research and Trials Center, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.
Noriko DokiHematology Division, Tokyo Metropolitan Komagome Hospital, Tokyo, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the leading cause of treatment failure in acute myeloid leukemia (AML), particularly in genetically adverse subtypes. Although prophylactic donor lymphocyte infusion (DLI) may augment graft-versus-leukemia effects, its stand-alone efficacy is suboptimal, necessitating rational combination approaches. Limited case reports have suggested potential clinical benefits of gemtuzumab ozogamicin (GO) in combination with DLI as salvage therapy for post-transplant relapse; however, its role in prophylactic maintenance has not been determined. We report a 29-year-old woman with chemo-refractory AML harboring t(1;3)(p36.3;q21) who relapsed approximately 3 months after her first allo-HSCT. She underwent a second haploidentical allo-HSCT without achieving remission beforehand. Given the extremely high risk of relapse, she received immune-directed maintenance with low-dose GO (3 mg/m

Indexed as

Antineoplastic Agents, ImmunologicalGemtuzumabHematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcuteLymphocyte TransfusionTranslocation, GeneticAdultFemaleGraft vs Host DiseaseHumansTreatment OutcomeAntineoplastic Agents, ImmunologicalGemtuzumabacute myeloid leukemiaallogeneic hematopoietic stem cell transplantationdonor lymphocyte infusiongemtuzumab ozogamicingraft-versus-leukemia effectpost-transplant maintenancet(1;3)(p36.3;q21)

Identifiers

PMID42620868
PMCPMC13485798

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.